Buprenorphine
FDA-approved product (film, extended release, transdermal), marketed as Brixadi, Buprenorphine, Butrans and 6 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Chronic pain
- Drug dependence
- Opioid dependence
- Opioid use disorder
- Overdose
- Pain
- Substance abuse
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Oripavine derivatives; Drugs used in opioid dependence
- FDA pharmacologic class
- Partial Opioid Agonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA56.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli44.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not docked: the structure could not be prepared for dockingdetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not docked: the structure could not be prepared for dockingdetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not docked: the structure could not be prepared for dockingdetails
Dihydrofolate reductase ↗ (MRSA)
Not docked: the structure could not be prepared for dockingdetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Buprenorphine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2
NCT00015041 · start 1996-11
Registered record
- Registry ID
- NCT00015041
- Conditions
- Opioid-Related Disorders; Substance-Related Disorders
- Interventions
- Buprenorphine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 1996-11
- Completion
- 1998-07
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpioid-Related Disorders; Substance-Related DisordersInterventionBuprenorphinePhasePhase 1Registry statusCompletedAlternate-Day Buprenorphine Administration. Phase II - 4
NCT00000222 · start 1992-07
Registered record
- Registry ID
- NCT00000222
- Conditions
- Opioid-Related Disorders
- Interventions
- Buprenorphine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 1992-07
- Completion
- Not recorded
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpioid-Related DisordersInterventionBuprenorphinePhasePhase 1Registry statusCompletedAlternate-Day Buprenorphine Administration. Phase I - 3
NCT00000221 · start 1992-04
Registered record
- Registry ID
- NCT00000221
- Conditions
- Opioid-Related Disorders
- Interventions
- Buprenorphine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 1992-04
- Completion
- Not recorded
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpioid-Related DisordersInterventionBuprenorphinePhasePhase 1Registry statusCompletedBuprenorphine Maintenance for Opioid Addicts - 2
NCT00000203 · start 1988-08
Registered record
- Registry ID
- NCT00000203
- Conditions
- Opioid-Related Disorders
- Interventions
- Buprenorphine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1988-08
- Completion
- 2006-05
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpioid-Related DisordersInterventionBuprenorphinePhasePhase 2Registry statusCompletedStudy Comparing Liquid and Tablet Buprenorphine Formulations - 5
NCT00000302
Registered record
- Registry ID
- NCT00000302
- Conditions
- Heroin Dependence
- Interventions
- Buprenorphine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeroin DependenceInterventionBuprenorphinePhasePhase 3Registry statusCompleted